[1]宋江南a,才 蕊b,张丹丹b,等.糖尿病肾病患者血清Maresin1 和PPBP 水平表达与远期预后的相关性研究[J].现代检验医学杂志,2024,39(03):164-169.[doi:10.3969/j.issn.1671-7414.2024.03.028]
　SONG Jiangnana,CAI Ruib,ZHANG Dandanb,et al.Correlation between the Expression of Serum Maresin1 and PPBP Levels and Long Term Prognosis in Patients with Diabetes Nephropathy[J].Journal of Modern Laboratory Medicine,2024,39(03):164-169.[doi:10.3969/j.issn.1671-7414.2024.03.028]
点击复制

糖尿病肾病患者血清Maresin1 和PPBP 水平表达与远期预后的相关性研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第39卷
期数:
2024年03期
页码:
164-169
栏目:
论著
出版日期:
2024-05-15

文章信息/Info

Title:
Correlation between the Expression of Serum Maresin1 and PPBP Levels and Long Term Prognosis in Patients with Diabetes Nephropathy
文章编号:
1671-7414（2024）03-164-06
作者:
宋江南1a; 才 蕊1b; 张丹丹1b; 孟 斌2; 田明杰1a
（1. 唐山中心医院a. 临床营养科；b. 内分泌科，河北唐山063000；2. 唐山市工人医院内分泌科，河北唐山 063000）
Author(s):
SONG Jiangnan1a; CAI Rui1b; ZHANG Dandan1b; MENG Bin2; TIAN Mingjie1a
(1a. Department of Clinical Nutrition；1b. Department of Endocrinology, Tangshan Central Hospital, Hebei Tangshan 063000, China；2. Department of Endocrinology, Tangshan Worker’s Hospital, Hebei Tangshan 063000, China)
关键词:
糖尿病肾病; Maresin1; 前血小板碱性蛋白
分类号:
R587.2；R446.61
DOI:
10.3969/j.issn.1671-7414.2024.03.028
文献标志码:
A
摘要:
目的 探讨糖尿病肾病（diabetes nephropathy，DN）患者血清Maresin1 和前血小板碱性蛋白（pro-plateletbasic protein，PPBP）表达水平及与远期预后的相关性。方法 选取2018 年5 月～ 2020 年5 月唐山市中心医院收治的83 例糖尿病肾病患者为糖尿病肾病组，并选取同期60 例单纯2 型糖尿病患者为糖尿病组和60 例健康体检者为对照组。采用酶联免疫吸附法（ELISA）检测血清Maresin1 和PPBP 水平，Spearman 相关性分析血清Maresin1，PPBP与肾病理损伤的相关性，COX 比例风险回归分析糖尿病肾病患者远期预后不良影响因素，受试者工作特征（ROC）曲线评估血清Maresin1 和PPBP 对远期预后不良的预测价值。结果 对照组、糖尿病组和糖尿病肾病组血清Maresin1水平（15.90±4.53ng/ml，12.34±4.29ng/ml，9.65±4.38ng/ml） 依次降低， 血清PPBP 水平（263.45±85.22pg/ml，349.28±80.49pg/ml，435.76±87.21pg/ml）依次升高，差异具有统计学意义（F=35.159，72.678，均P<0.05）。随着IFTA 评分、间质炎症评分、肾小球分级的增加血清Maresin1 水平降低（F=25.838，25.187，9.751，均P<0.05），血清PPBP 水平升高（F=56.513，92.702，58.137，均P<0.05），差异具有统计学意义。血清Maresin1 与IFTA 评分、间质炎症评分、肾小球分级呈负相关（r=-0.637，-0.581，-0.594，均P<0.05），血清PPBP 与IFTA 评分、间质炎症评分、肾小球分级呈正相关（r=0.659，0.664，0.608，均P<0.05）。糖尿病肾病病程（HR=1.135，95%CI：1.012 ～ 1.370）、24h 尿蛋白（HR=1.087，95%CI：1.016 ～ 1.164）、PPBP（HR=1.208，95%CI：1.119 ～ 1.365）、IFTA 评分（HR=1.139，95%CI：1.024 ～ 1.219）、间质炎症评分（HR=1.122，95%CI：1.006 ～ 1.249）和肾小球分级（HR=1.139，95%CI：1.052 ～ 1.273）是糖尿病肾病患者远期预后的独立危险因素；eGFR（HR=0.934，95%CI：0.892 ～ 0.993）和Maresin1（HR=0.903，95%CI：0.816 ～ 0.982）是远期预后的保护因素（均P<0.05）。血清Maresin1，PPBP 及两指标联合预测糖尿病肾病患者远期预后不良的曲线下面积（AUC）分别为0.781，0.777 和0.901，两指标联合预测的AUC 高于单项指标预测，差异具有统计学意义（Z=3.049，3.258，均P<0.05）。结论 糖尿病肾病患者血清Maresin1 水平降低，PPBP 水平升高，两指标与肾损伤程度密切相关，联合检测可有效预测患者远期不良预后。
Abstract:
Objective To investigate the expression of serum Maresin 1 and pro-platelet basic protein (PPBP) in patients with diabetes nephropathy（DN）and their correlation with long-term prognosis. Methods A total of 83 patients with diabetes nephropathy admitted to Tangshan Central Hospital from May 2018 to May 2020 were selected as the diabetes nephropathy group. In the same period, 60 patients with simple type 2 diabetes were selected as the diabetes group and 60 healthy people as the control group. Enzyme linked immunosorbent assay (ELISA) was used to detect the levels of serum Maresin1 and PPBP. Spearman correlation analysis was used to analyze the correlation between the levels of serum Maresin1 and PPBP and renal pathological damage. COX proportional hazard regression analysis was used to analyze the factors influencing the long-term poor prognosis of patients with diabetes nephropathy. ROC curve was used to evaluate the predictive value of serum Maresin1 and PPBP for the long-term poor prognosis. Results The levels of serum Maresin1 (15.90 ± 4.53 ng/ml, 12.34 ± 4.29 ng/ml, 9.65 ± 4.38 ng/ml) in the control group, diabetes group and diabetes nephropathy group were decreased in turn while the levels of serum PPBP (263.45 ± 85.22 pg/ml, 349.28 ± 80.49 pg/ml, 435.76 ± 87.21 pg/ml) were increased in turn, and the differences were statistically significant (F=35.159，72.678，all P<0.05). With the increase of IFTA score, interstitial inflammation score, and glomerular grading, serum Maresin1 level was decreased (F=25.838，25.187，9.751，all P<0.05), while serum PPBP level was increased (F=56.513，92.702，58.137，all P<0.05), and the differences were statistically significant,respectively. Serum Maresin1 was negatively correlated with IFTA score, interstitial inflammation score, and glomerular grading (r=-0.637, -0.581, -0.594, all P<0.05), while serum PPBP was positively correlated with IFTA score, interstitial inflammation score, and glomerular grading (r=0.659, 0.664, 0.608, all P<0.05), with significant differences. The course of diabetes nephropathy (HR=1.135, 95% CI: 1.012 ～ 1.370), 24-hour urinary protein (HR=1.087, 95% CI: 1.016 ～ 1.164), PPBP (HR=1.208, 95% CI: 1.119 ～ 1.365), and IFTA score (HR=1.139, 95% CI: 1.024 ～ 1.219), interstitial inflammation score (HR=1.122, 95% CI: 1.006 ～ 1.249) and glomerular grading (HR=1.139, 95% CI: 1.052 ～ 1.273) were independent risk factors for long-term prognosis of diabetes nephropathy patients, while eGFR (HR=0.934, 95% CI: 0.892 ～ 0.993) and Maresin1 (HR=0.903, 95% CI: 0.816 ～ 0.982) were protective factors for long-term prognosis (all P<0.05). The areas under the curve (AUC) of serum Maresin1, PPBP and two indicators combined to predict the long-term poor prognosis of patients with diabetes nephropathy were 0.781, 0.777 and 0.901, respectively. The AUC of two indicators combined was higher than that,and the differences were significant (Z=3.049, 3.258, all P<0.05). Conclusion In patients with diabetes nephropathy, serum Maresin1 was decreased and PPBP was increased, and the two indexes were closely related to the degree of renal injury. The combined test could effectively predict the long-term poor prognosis of patients.

参考文献/References:

[1] LI Sicheng, XIE Huidi, SHI Yang, et al. Prevalence of diabetic nephropathy in the diabetes mellitus population: A protocol for systematic review and metaanalysis[J]. Medicine, 2022, 101(42): e31232.
[2] HOCHER B, TSUPRYKOV O. Diabetic nephropathy:renoprotective effects of GLP1R agonists and SGLT2 inhibitors[J]. Nature Reviews Nephrology, 2017,13(12): 728-730.
[3] 王家芷, 王成, 寿岚. 血清miR-130b 与糖尿病肾病患者肾脏损伤及远期预后的相关性研究[J]. 中国中西医结合肾病杂志, 2019, 20(4): 316-318. WANG Jiazhi, WANG Cheng, SHOU Lan. Study on the correlation between serum miR-130b and renal injury and long-term prognosis in patients with diabetes nephropathy[J]. Chinese Journal of Integrated Traditional and Western Nephrology, 2019, 20(4): 316-318.
[4] 鲁文菊, 宫艳艳, 高霞, 等. 2 型糖尿病肾病患者外周血E- 选择素表达水平及其基因G98T 和A561C位点多态性与代谢指标的相关性研究[J]. 现代检验医学杂志, 2022, 37(5): 81-85, 153. LU Wenju, GONG Yanyan, GAO Xia, et al. Association of E-selectin and its gene G98T and A561C polymorphisms with type 2 diabetic nephropathy[J].Journal of Modern Laboratory Medicine, 2022, 37(5):81-85, 153.
[5] SAITO-SASAKI N, SAWADA Y, NAKAMURA M. Maresin-1 and inflammatory disease[J]. International Journal of Molecular Sciences, 2022, 23(3): 1367.
[6] WAHYUNI T, KOBAYASHI A, TANAKA S, et al.Maresin-1 induces cardiomyocyte hypertrophy through IGF-1 paracrine pathway[J]. American Journal of Physiology-Cell Physiology, 2021, 321(1): C82-C93.
[7] WANG Fuquan, WANG Min, WANG Jingxu, et al. Maresin1 ameliorates sepsis-associated lung injury by inhibiting the activation of the JAK2/STAT3 and MAPK/ NF-κB signaling pathways[J]. Microbial Pathogenesis, 2020, 148: 104468.
[8] ZHANG Fengxia, JIANG Nan, GAO Yan, et al. PPBP as a marker of diabetic nephropathy podocyte injury via bioinformatics analysis[J]. Biochemical and Biophysical Research Communications, 2021, 577:165-172.
[9] 中华医学会内分泌学分会. 中国成人糖尿病肾脏病临床诊断的专家共识[J]. 糖尿病天地(临床), 2016,10(6): 243-253. Chinese Society of Endocrinology, Chinese Medical Association. Expert consensus on clinical diagnosis of adult diabetes nephropathy in China[J].Diabetes World(Clinical), 2016, 10(6): 243-253.
[10] 周仕群, 王聪, 江强, 等. 糖尿病肾病患者血清miR-188-5p 及miR-379-5p 的表达及其临床意义[J]. 现代检验医学杂志, 2022, 37(3): 91-95. ZHOU Shiqun, WANG Cong, JIANG Qiang, et al. Expression and clinical significance of serum miR-188-5p and miR-379-5p in patients with diabetic nephropathy[J]. Journal of Modern Laboratory Medicine, 2022, 37(3): 91-95.
[11] 祁桠楠, 胡江伟, 武亮, 等. 血清TLR-3, miR-181b及URBP 联合检测在糖尿病肾病诊断及预后判断的价值研究[J]. 现代检验医学杂志, 2022, 37(2): 37-41. QI Ya’nan, HU Jiangwei, WU Liang, et al. Value of combined detection of serum TLR-3, miR-181b and URBP in diagnosis and prognosis of diabetic nephropathy[J]. Journal of Modern Laboratory Medicine, 2022,37(2): 37-41.
[12] RASTOGI A, BHATT N, ROSSETTI S, et al. Management of hyperphosphatemia in end-stage renal disease:a new paradigm[J]. Journal of Renal Nutrition, 2021,31(1): 21-34.
[13] WARREN A M, KNUDSEN S T, COOPER M E. Diabetic nephropathy: an insight into molecular mechanisms and emerging therapies[J]. Expert Opinion on Therapeutic Targets, 2019, 23(7): 579-591.
[14] 张关亭. CysC, β2 微球蛋白、肌酐、尿素氮在2 型糖尿病肾病不同阶段的水平变化及诊断价值[J]. 中华全科医学, 2017, 15(5): 850-852. ZHANG Guanting. Change of cystatin C, β2-microglobulin, creatinine and blood urea Nitrogen in different stages of type 2 diabetic nephropathy and their diagnostic value[J]. Chinese Journal of General Practice, 2017, 15(5): 850-852.
[15] RODR?GUEZ M J, SABAJ M, TOLOSA G, et al. Maresin-1 prevents liver fibrosis by targeting Nrf2 and NF-κB, reducing oxidative stress and inflammation[J].Cells, 2021, 10(12): 3406.
[16] IM D S. Maresin-1 resolution with RORα and LGR6[J]. Progress in Lipid Research, 2020, 78:101034.
[17] 李泽, 单伟, 姜东. Maresin1 对糖尿病大鼠肾脏损伤的保护作用及机制研究[J]. 陕西医学杂志, 2022,51(12): 1467-1471. LI Ze, SHAN Wei, JIANG Dong. Protective effect and mechanism of Maresin1 on renal injury in diabetic rats[J]. Shaanxi Medical Journal, 2022, 51(12): 1467-1471.
[18] ZHANG Zhanwei, JI Chonghao, WANG Ya’nan, et al. Maresin1 suppresses high-glucose-induced ferroptosis in osteoblasts via NRF2 activation in type 2 diabetic osteoporosis[J]. Cells, 2022, 11(16): 2560.
[19] ZHAO Mengmeng, LI Chenfei, ZHANG Jishou,et al. Maresin-1 and its receptors RORα/LGR6 as potential therapeutic target for respiratory diseases[J].Pharmacological Research, 2022, 182: 106337.
[20] GRACA F A, STEPHAN A, MINDEN-BIRKENMAIER B A, et al. Platelet-derived chemokines promote skeletal muscle regeneration by guiding neutrophil recruitment to injured muscles[J]. Nature Communications,2023, 14(1): 2900.
[21] 周罗绮, 赵新玲, 郭虹, 等. 前血小板碱性蛋白对急性缺血性脑卒中的诊断意义[J]. 神经损伤与功能重建, 2018, 13(8): 379-382. ZHOU Luoqi, ZHAO Xinling, GUO Hong, et al. Significance of pro-platelet basic protein in diagnosis of acute ischemic stroke[J]. Neural Injury and Functional Reconstruction, 2018, 13(8): 379-382.
[22] QIN Chuan, ZHAO Xinling, MA Xiaotong, et al. Proteomic profiling of plasma biomarkers in acute ischemic stroke due to large vessel occlusion[J]. Journal of Translational Medicine, 2019, 17(1): 214.
[23] MANSANGUAN C, MANEERAT Y. PPBP gene as a biomarker for coronary heart disease risk in postmenopausal Thai women[J]. Peer J, 2022,10:e13615.
[24] MANEERAT Y, PRASONGSUKARN K, BENJATHUMMARAK S, et al. PPBP and DEFA1/DEFA3 genes in hyperlipidaemia as feasible synergistic inflammatory biomarkers for coronary heart disease[J]. Lipids in Health and Disease, 2017, 16(1): 80.
[25] ZHAO Hongtao, DONG Jiawei, ZHANG Jiheng, et al. Expression of intra-tumoral necrosis-associated cytokine pattern correlated with prognosis and immune status in glioma[J]. Frontiers in Molecular Neuroscience, 2023, 16: 1117237.
[26] XING Na, DONG Ziye, WU Qiaoli, et al. Identification and validation of key molecules associated with humoral immune modulation in Parkinson’s disease based on bioinformatics[J]. Frontiers in Immunology,2022, 13: 948615.
[27] MOIN A S M, NANDAKUMAR M, AL-QAISSI A,et al. Potential biomarkers to predict acute ischemic stroke in type 2 diabetes[J]. Frontiers in Molecular Biosciences, 2021, 8: 744459.

相似文献/References:

[1]张春雷,曾学辉,李忠新,等.尿KIM-1和NGAL在糖尿病肾病早期诊断中的应用[J].现代检验医学杂志,2015,30(01):52.[doi:10.3969/j.issn.1671-7414.2015.01.014]
　ZHANG Chun-lei,ZENG Xue-hui,LI Zhong-xin,et al.Value of Urinary KIM-1 and NGAL in Predicting the Early Diabetic Nephropathy[J].Journal of Modern Laboratory Medicine,2015,30(03):52.[doi:10.3969/j.issn.1671-7414.2015.01.014]
[2]阿地拉·阿布里孜,王 霞,屈晓威.联合检测视黄醇结合蛋白和膜联蛋白A2水平对糖尿病肾病早期诊断的意义[J].现代检验医学杂志,2016,31(05):118.[doi:10.3969/j.issn.1671-7414.2016.05.033]
　ADILA·Abulizi,WANG Xia,QU Xiao-wei.Significance of Combined Detection of Serum Retinol-Binding Protein and AnnexinA2 in Diabetic Nephropathy[J].Journal of Modern Laboratory Medicine,2016,31(03):118.[doi:10.3969/j.issn.1671-7414.2016.05.033]
[3]于菲菲,庞白冰,杨 华,等.单纯性2型糖尿病与糖尿病肾病患者尿液中α1-微球蛋白和激肽原1的表达分析[J].现代检验医学杂志,2017,32(05):94.[doi:10.3969/j.issn.1671-7414.2017.05.017]
　YU Fei-fei,PANG Bai-bing,YANG Hua,et al.Expression Analysis of α1-Microglobulin,Kininogen1 in Urine of Simple Type 2 Diabetes and Diabetic Nephropathy Patients[J].Journal of Modern Laboratory Medicine,2017,32(03):94.[doi:10.3969/j.issn.1671-7414.2017.05.017]
[4]吴忠璟,陈亚凤,高芳虹.糖尿病肾病患者血清miR-135b水平检测与疾病预后的相关性研究[J].现代检验医学杂志,2018,33(03):88.[doi:10.3969/j.issn.1671-7414.2018.03.022]
　WU Zhong-jing,CHEN Ya-feng,GAO Fang-hong.Correlation between Serum miR-135b Level and Prognosis in Patients with Diabetic Nephropathy[J].Journal of Modern Laboratory Medicine,2018,33(03):88.[doi:10.3969/j.issn.1671-7414.2018.03.022]
[5]杨翠伶.血清miR-150-5p和miR-155-5检测对老年糖尿病肾病的诊断价值[J].现代检验医学杂志,2018,33(05):74.[doi:10.3969/j.issn.1671-7414.2018.05.020]
　YANG Cui-ling.Diagnostic Value of Serum miR-150-5p and miR-155-5 Detection in Elderly Diabetic Nephropathy[J].Journal of Modern Laboratory Medicine,2018,33(03):74.[doi:10.3969/j.issn.1671-7414.2018.05.020]
[6]谭志敏,张 燕,滕雅娟,等.糖尿病肾病患者血清甲状腺激素水平变化及其与亚临床甲状腺功能减退的相关性[J].现代检验医学杂志,2018,33(06):95.[doi:10.3969/j.issn.1671-7414.2018.06.025]
　TAN Zhi-min,ZHANG Yan,TENG Ya-juan,et al.Correlation between Serum Thyroid Hormone Levels in Patients with Diabetic Kidney Disease and Subclinical Hypothyroidism[J].Journal of Modern Laboratory Medicine,2018,33(03):95.[doi:10.3969/j.issn.1671-7414.2018.06.025]
[7]张求霞a,汪隆海a,昌国庆a,等.尿液6种蛋白与CysC水平检测对糖尿病肾病的诊断价值[J].现代检验医学杂志,2019,34(01):67.[doi:10.3969/j.issn.1671-7414.2019.01.017]
　ZHANG Qiu-xiaa,WANG Long-haia,CHANG Guo-qing a,et al.Clinical Value of Detection of 6 Proteins and Cystatin C in Urine for Early Diagnosis of Diabetic Kidney Disease[J].Journal of Modern Laboratory Medicine,2019,34(03):67.[doi:10.3969/j.issn.1671-7414.2019.01.017]
[8]张曙晴,张骆军,李洪彬,等.血液小而密低密度脂蛋白胆固醇、抗凝血酶Ⅲ水平及血小板参数检测在2型糖尿病肾病中的应用价值研究[J].现代检验医学杂志,2021,36(02):70.[doi:doi:10.3969/j.issn.1671-7414.2021.02.017]
　ZHANG Shu-qing,ZHANG Luo-jun,LI Hong-bin,et al.Study on the Application Value of Detecting Small Dense Low-density Lipoprotein Cholesterol, Antithrombin-Ⅲ Levels and Platelet Parameter in the Patients with Type-2 Diabetic Nephropathy[J].Journal of Modern Laboratory Medicine,2021,36(03):70.[doi:doi:10.3969/j.issn.1671-7414.2021.02.017]
[9]闫海燕,杨云秀,杨云华,等.老年糖尿病肾病患者血清SP-D水平表达及其基因多态性与并发肺部感染的相关性研究[J].现代检验医学杂志,2021,36(04):21.[doi:10.3969/j.issn.1671-7414.2021.04.005]
　YAN Hai-yan,YANG Yun-xiu,YANG Yun-hua,et al.Research on the Relationship between Serum SP-D Level, Gene Olymorphismand Pulmonary Infection in Elderly Patients with Diabetic Nephropathy[J].Journal of Modern Laboratory Medicine,2021,36(03):21.[doi:10.3969/j.issn.1671-7414.2021.04.005]
[10]祁桠楠a,胡江伟b,武　亮c,等.血清TLR-3，miR-181b及URBP联合检测在糖尿病肾病诊断及预后判断的价值研究[J].现代检验医学杂志,2022,37(02):37.[doi:10.3969/j.issn.1671-7414.2022.02.008]
　QI Ya-nana,HU Jiang-weib,WU Liangc,et al.Value of Combined Detection of Serum TLR-3, miR-181b and URBP in Diagnosis and Prognosis of Diabetic Nephropathy[J].Journal of Modern Laboratory Medicine,2022,37(03):37.[doi:10.3969/j.issn.1671-7414.2022.02.008]

备注/Memo

备注/Memo:
基金项目：河北省医学科学研究课题计划（编号：20211274）。
作者简介： 宋江南（1987-），女，硕士研究生，主治医师，研究方向：慢性病、恶性肿瘤患者的营养治疗，E-mail：songjiangnan6544@126.com。
通讯作者：田明杰（1985-），男，硕士研究生，主治医师，研究方向：慢性病、重症患者的营养治疗，E-mail：tsnutrition@163.com。
更新日期/Last Update: 2024-05-15